SELLAS Life Sciences (SLS) Receivables - Accured (2017)
SELLAS Life Sciences (SLS) posted quarterly Receivables - Accured of $800000.0 for Q4 2017.
Powered by 
Analysis
SELLAS Life Sciences (SLS) Receivables - Accured (2017) Analysis & Trends
SELLAS Life Sciences (SLS) has reported Receivables - Accured for 1 consecutive years, with $800000.0 the latest figure, recorded in Q4 2017.
- In Q4 2017, Receivables - Accured changed N/A year-over-year to $800000.0; the TTM figure through Dec 2017 stood at $800000.0 (changed N/A YoY), while the FY2017 annual figure was $800000.0, changed N/A from the prior year.
- Receivables - Accured held at $800000.0 in Q4 2017 per SLS's latest filing.
- Across five years, Receivables - Accured topped out at $800000.0 in Q4 2017 and bottomed at $800000.0 in Q4 2017.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables - Accured (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | SELLAS Life Sciences | 2.62 Bn | 2.62 Bn | - | - |